HEALTHCARE/OBAMACARE(ACA): "A high-profile meeting Tuesday [1-31-17] with a president who accused the drug industry of getting away with murder could have ended badly for the big pharma companies.
Though he said drug price increases have been 'astronomical' and vowed to thoughen Medicare negotiation practices, President Donald Trump pledged to speed up regulatory approvals for new drugs and make th eprocess less expensive, a positive for the pharma industry, especially smalleer biotechs."

 – “Surviving a Trump Meeting Doesn���t Mean All Clear for Drug Industry,” The Wall Street Journal online, Jan. 31, 2017, Charley Grant, 1/31/2017